martes, 12 de febrero de 2019

Drug patent protection: it's time for a 'one-and-done' approach - STAT

Drug patent protection: it's time for a 'one-and-done' approach - STAT



Opinion: ‘One-and-done’ for new drugs could cut patent thickets and boost generic competition

By ROBIN FELDMAN


ADOBE
That approach to drug patents that gives companies a single period of exclusivity could prevent the patent thickets that stifle generic competition.

No hay comentarios: